Anthracycline News and Research

RSS
Anthracycline is a type of antibiotic that comes from certain types of Streptomyces bacteria. Anthracyclines are used to treat many types of cancer. Anthracyclines damage the DNA in cancer cells, causing them to die. Daunorubicin, doxorubicin, and epirubicin are anthracyclines.
NCCN Guidelines for Acute Myeloid Leukemia updated

NCCN Guidelines for Acute Myeloid Leukemia updated

Rituxan's sBLA receives a Complete Response from the FDA

Rituxan's sBLA receives a Complete Response from the FDA

Breast cancer patients who achieve pathological complete response have better outcomes

Breast cancer patients who achieve pathological complete response have better outcomes

Orphan drug designation for pixantrone applied by Cell Therapeutics

Orphan drug designation for pixantrone applied by Cell Therapeutics

Genentech releases Phase III PRIMA study findings

Genentech releases Phase III PRIMA study findings

Phase III EXTEND trial results of pixantrone announced

Phase III EXTEND trial results of pixantrone announced

Cell Therapeutics submits Pediatric Investigation Plan to EMEA for pixantrone

Cell Therapeutics submits Pediatric Investigation Plan to EMEA for pixantrone

Cytrx initiates tamibarotene and TRISENOX combination dose escalation study

Cytrx initiates tamibarotene and TRISENOX combination dose escalation study

FDA approves Supplemental New Drug Application for DOXIL

FDA approves Supplemental New Drug Application for DOXIL

FDA notifies PDUFA action date for Cell Therapeutics' NDA for pixantrone

FDA notifies PDUFA action date for Cell Therapeutics' NDA for pixantrone

Chemotherapy affects sleep-wake activity rhythms of breast cancer patients

Chemotherapy affects sleep-wake activity rhythms of breast cancer patients

Cell Therapeutics' NDA for Pixantrone accepted by the FDA

Cell Therapeutics' NDA for Pixantrone accepted by the FDA

Genentech announces Phase III study results for Avastin (bevacizumab) in combination with chemo in HER2-negative breast cancer

Genentech announces Phase III study results for Avastin (bevacizumab) in combination with chemo in HER2-negative breast cancer

U.S. District Court rules against Lilly regarding Gemzar patent

U.S. District Court rules against Lilly regarding Gemzar patent

Genentech and Biogen Idec submit applications to FDA for Rituxan in chronic lymphocytic leukemia

Genentech and Biogen Idec submit applications to FDA for Rituxan in chronic lymphocytic leukemia

Combining two chemotherapy drugs with Herceptin shows promise for metastatic HER2+ breast cancer

Combining two chemotherapy drugs with Herceptin shows promise for metastatic HER2+ breast cancer

Gene alterations associated with response to anthracycline therapy for breast cancer

Gene alterations associated with response to anthracycline therapy for breast cancer

Study of Rituxan (rituximab) in lupus nephritis misses primary endpoint

Study of Rituxan (rituximab) in lupus nephritis misses primary endpoint

Researchers show how anthracycline class of chemotherapeutics block blood vessel growth, slow cancer spread

Researchers show how anthracycline class of chemotherapeutics block blood vessel growth, slow cancer spread

New research moves us one step closer to personalised breast cancer treatment

New research moves us one step closer to personalised breast cancer treatment